FDA: Doctors should use genetic test before prescribing abacavir
The FDA is expected to release an advisory today that calls on doctors to use a genetic test before prescribing abacavir -- sold by GlaxoSmithKline under the name Ziagen -- to prevent severe allergic reactions in patients carrying an immune-system gene variant. The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on "inconclusive" study data.
New York Times, The | 07/24
This story published in AABB SmartBrief on 07/24/2008
More from SmartBrief:
Novartis' Exjade might cause serious complications, FDA says
Monday, September 28, 2009
Immucor submits 30-day working response to FDA
Tuesday, August 11, 2009
Registration now open for FDA workshop on emerging arboviruses
Monday, November 2, 2009
Get stories like these delivered daily for FREE:
|
AABB SmartBrief
Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more |
|